On November 12, 2014, Structured Products held its annual regulatory, compliance and legal conference in Washington, D.C. Conference attendees had the opportunity to hear from federal and state securities regulators, FINRA officials, as well as other leading market participants, as to current areas of focus and other guidance. In this article, we report on a number of the most significant statements and reminders that industry regulators shared with the audience.1

The SEC and Structured Products

Amy Starr, from the SEC’s Office of Capital Markets Trends (the “OCMT”), led off the conference. After providing a brief overview of the OCMT and its recent activities, she discussed the SEC’s 2014 “sweep letter” relating to exchange traded notes (ETNs). The text of the letter does not appear on the SEC website; however, a number of significant issuers of ETNs received a substantially similar letter. The process was characterized as a “private review.” Among the concerns of the OCMT are that ETN prospectus disclosures as to the “indicative value” of an ETN are not always clear, and that the meaning of this term can vary from issuer to issuer. The OCMT also sought to ensure that ETN disclosures explained the difference between the ETN’s indicative value, its trading value and the value of the underlier, and the meaning of similar terms used in some offering documents, such as “intrinsic economic value” as that term relates to the indicative value. Consistent with recent efforts and statements by securities regulators, the OCMT asked that issuers disclose how investor fees and any other fees associated with the ETNs are reflected in indicative values.

Ms. Starr next focused on issues relating to the selection of underlying assets relating to SEC-registered structured products. She discussed the OCMT’s views relating to the SEC’s 1996 “Morgan Stanley” no action letter,indicating that the OCMT believed that it remained relevant guidance for market participants today. There are a number of ways in which the letter affects prevailing practices in the registered market:

  • Per the OCMT’s 2012 sweep letter to structured note issuers, issuers should not disclaim responsibility for the accuracy of information included in a prospectus about an underlying asset.
  • Non-actively managed exchanged traded funds, such as those that track a broad market index, remain eligible for use as reference assets in registered structured products; however, the OCMT does not believe that actively managed ETFs are eligible reference assets for a SEC-registered product.
  • Credit-linked notes, in which the return of the structured product would depend upon whether or not a “credit event” occurs as to one or more underlying issuers, were not viewed as permissible for SEC-registered notes. There is a degree of doubt as to whether an underlying issuer’s 1934 Act reports would include information that investors could readily access in order to determine whether such an event occurred.
  • Notes linked to hedge funds and hedge fund indices would not be appropriate for SEC-registered notes, due to the lack of public information about the underlying hedge funds and their strategies.

Market participants were also reminded to consider the disclosures and other potential issues when a registered note is linked to an index that has a high concentration of one or more particular stocks. In these cases, an investor’s return may depend to a large extent on the index components that represent a significant concentration in the index.

Outside of the context of registered securities, practices may differ in some cases. For example, the audience was reminded that structured products that are not issued pursuant to a registration statement, such as structured CDs, bank notes, Rule 144A offerings and Regulation D offerings, were outside the scope of the Morgan Stanley letter. Accordingly, a broader range of underlying assets may be considered for use, as compared to a registered offering.3

The Backtested Data Debate

A panel discussion among regulators vividly displayed the contrasting approaches of the U.S. securities regulators as to the disclosure of backtested information (pre-inception performance) for indices.

To illustrate the starkness of the divide, here is a summary table:

Click here to view table.

Amy Starr reiterated the view of the SEC staff that this type of information is permitted, as long as the information is presented appropriately. Many of the guidelines identified in FINRA’s 2013 “ALPS letter”are appropriate to consider here when this type of information is included in a prospectus.

In contrast, Tom Selman, FINRA’s Executive Vice President of Investment Companies Regulation, reiterated FINRA’s view that this information is not permitted in retail communications under FINRA’s advertising rules. FINRA views it as “fraught with peril,” due to potential data mining (“cherry picking”) and other issues. However, FINRA is currently reviewing its advertising rules in all respects, and may (or may not) reconsider this position.

FINRA and SEC Review of Broker Dealers

A panel discussion among various regulators indicated a number of key areas of regulatory focus. The panel consisted of Daniel Gregus, Acting Associate Regional Director, Broker-Dealer Examinations, Chicago Regional Office of the SEC; Reid Muoio, Deputy Chief, Structured New Products Unit, Division of Enforcement of the SEC; Mark Fernandez, Senior Regional Counsel, Department of Enforcement of FINRA; and Ronak Patel, Deputy Securities Commissioner, of the Texas State Securities Board. A number of the key issues addressed have come to the fore during the last two years, in light of, for example, FINRA’s 2013 report on Conflicts of Interest.5

KYD Procedures. Brokers are expected to review the third party distributors that sell the complex products that they originate. Among the factors to consider are their sales practices, training, investor education efforts, and compliance culture. FINRA members should review how these distributors code their sales of complex products, in order to identify over-concentration or other potential issues. FINRA has endorsed, in appropriate cases, a “tiered distribution model,” to reflect the possibility that some distributors may be selected to distribute only less complex products, but may not be permitted to sell the more complicated product offerings.

Post-Issuance Review. Brokers are obligated to perform a post-issuance review after rolling out a new complex product. A review would include, for example, an assessment of whether a product performed in accordance with its design, and whether distributors and other sellers sold the product to the types of investors for which it was intended. Needless to say, FINRA would be concerned if a product designed for institutional investors was shown to in fact frequently end up in the hands of retail investors.

Reverse Inquiry Transactions. In reverse inquiry transactions, an investor seeks out a structured product with a specified return profile. Appropriate KYD procedures and “reasonable basis suitability” determinations may also be needed for these types of offerings as well, notwithstanding the fact that the broker itself did not initially conceive the instrument. In addition, brokers should exercise appropriate caution, and perform appropriate approval procedures, before rolling out a product that commenced as a reverse inquiry product to additional investors, particularly in the case of retail investors.

Branch Offices. In many cases, a broker’s branch offices may have fewer resources and, accordingly, less robust procedures and training, than the broker’s main office. Mr. Fernandez noted that one of FINRA’s 2015 exam priorities will be to help evaluate the risk matrix used in connection with branch offices, particularly in connection with sales of complex products.

FINRA Advertising Rules

Since FINRA’s amended advertising rules went into effect in February 2013,a variety of interpretative questions have arisen. FINRA attempted to resolve some of these questions in its 2014 rule amendments.7 Notwithstanding the amendments, a variety of questions and different practices have emerged. As part of his presentation to the conference, and subsequently as part of a panel, David Roscum, Manager of FINRA’s Advertising Regulation Department, attempted to provide some clarification as to the application of the advertising rules and related filing requirements to structured products.

Generic Materials. Generic materials, such as brochures relating to one or more different product types generally, are not subject to the filing requirements. This is because such materials do not relate to “any [specific] security,” as that concept is contemplated by FINRA Rule 2210(c)(3)(E). Instead, FINRA’s filing requirement, according to Mr. Roscum, relates to retail communications that describe specific securities.

Who “Owns” the Free Writing Prospectus (FWP)? The filing rules exempt from FINRA filings most prospectuses and free writing prospectuses that the issuer files with the SEC (FINRA Rule 2210(c)(7)(F)). In the case of an FWP in which both the issuer and the underwriter have a role in preparation, including where the issuer is an affiliate of the underwriter,

Mr. Roscum indicated that the issuer’s filing of the document under SEC Rule 433 would be sufficient to remove the document from FINRA’s filing requirements.

Templates. Many types of FWPs, such as summary descriptions of particular types of offerings, repeat themselves on a monthly or weekly basis. However, the FINRA filing rules were developed without the possibility of filing a single template for multiple similar offerings. The FINRA advertising department would be open to the possibility of discussing with issuers the possible approval of templates for multiple offerings, but with a single filing made.

Offerings Outside the Scope of the Advertising Rule. Mr. Roscum indicated that offerings conducted solely outside the U.S., and offerings of structured certificates of deposit (which typically are not “securities”), are not within the scope of the advertising rules, and the relevant offering documents should not be filed with FINRA.

As a general matter, FINRA believes that the quality of materials being filed with FINRA that relate to structured products is improving. And where issuers thought they had documents or materials that might raise broader, more interesting, questions under the FINRA rules, he encouraged brokers to reach out directly to their designated analyst in order to discuss the form and content of the materials in question.

Conclusion

The Washington conference reflects the continued effort by market participants to understand, and comply with, their regulatory requirements, as well as the regulators’ desire to understand and communicate with the market. Meetings of this kind help ensure that investors benefit from the continuing improvement and refinement of industry practices.